<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03241043</url>
  </required_header>
  <id_info>
    <org_study_id>PAKT CTC 151043</org_study_id>
    <nct_id>NCT03241043</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Pharmacokinetic and Bioavailability of Envarsus® vs. Advagraf® in Liver Transplant Recipients</brief_title>
  <official_title>Single Center, Open-label, Randomized, Controlled, Cross Over Study to Evaluate the Pharmacokinetic and Bioavailability of Envarsus® in Comparison to Advagraf® in de Novo Liver Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single centre, open-label, randomized, controlled, cross over study to evaluate the&#xD;
      pharmacokinetic and bioavailability of Envarsus® in comparison to Advagraf® in de novo liver&#xD;
      transplant recipients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Using an open-label, randomized, controlled, 2-period cross-over design, two treatments&#xD;
      (Envarsus® and Advagraf®) will be compared (with regard to PK profile and bioavailability)&#xD;
      after administration of IMP to 20 de novo transplanted recipients. The patients will be&#xD;
      randomly assigned to one of the two treatments as treatment period 1 and afterwards switched&#xD;
      to treatment period 2 (Group 1: Envarsus® - Advagraf®; Group 2: Advagraf® - Envarsus®).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">April 2019</completion_date>
  <primary_completion_date type="Actual">April 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DAV (average cumulative dose) = cumulative dose per study period/ period days</measure>
    <time_frame>20 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>C0/doses (trough level at steady state / daily dose at steady state)</measure>
    <time_frame>20 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-24/doses</measure>
    <time_frame>20 month</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>Envarsus - Advagraf</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Advagraf - Envarsus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment 2 weeks Envarsus followed by 2 weeks Advagraf</intervention_name>
    <arm_group_label>Envarsus - Advagraf</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment 2 weeks Advagraf followed by 2 weeks Envarsus</intervention_name>
    <arm_group_label>Advagraf - Envarsus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability to understand the patient information and to personally sign and date the&#xD;
             informed consent to participate in the clinical trial, before completing any clinical&#xD;
             trial related procedures.&#xD;
&#xD;
          2. Male or female recipients ≥ 18 years of a liver graft from a deceased or living donor&#xD;
&#xD;
          3. The patient must receive a twice daily Tacrolimus based immunosuppression treatment.&#xD;
&#xD;
          4. Females of child-bearing potential who agree to comply with any applicable&#xD;
             contraceptive requirements of the protocol or females who are permanently sterilized&#xD;
             (at least 6 weeks post sterilization).&#xD;
&#xD;
          5. Non-pregnant, non-lactating female.&#xD;
&#xD;
          6. Recipients of a first or re-liver transplant in the last 30 days&#xD;
&#xD;
          7. The patient is co-operative and available for the entire clinical trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with a known hypersensitivity to any of the drugs used in the study.&#xD;
&#xD;
          2. Patients who are not able to take oral medication at the time point of randomization.&#xD;
&#xD;
          3. Recipients of combined organ transplants.&#xD;
&#xD;
          4. Patients who are recipients of AB0 incompatible transplant grafts.&#xD;
&#xD;
          5. Currently participation in a clinical trial and any IMP intake within the last four&#xD;
             weeks.&#xD;
&#xD;
          6. Patients who use drugs known to strongly interact with the cytochrome P-450 3A4&#xD;
             pathway and therefore influence the tacrolimus blood level are not allowed during&#xD;
             Envarsus®/Advagraf® treatment period.&#xD;
&#xD;
          7. Patient with renal impairment with need of dialysis treatment at the time point of&#xD;
             randomization.&#xD;
&#xD;
          8. Patient with a quick value &lt; 30 %&#xD;
&#xD;
          9. Patient with a thrombocytopenia &lt;20 Mrd./L&#xD;
&#xD;
         10. Patients with a leukopenia &lt; 1.0 Mrd. / L&#xD;
&#xD;
         11. Patients with inability of oral food intake.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herden</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 12, 2016</study_first_submitted>
  <study_first_submitted_qc>August 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2017</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetic study</keyword>
  <keyword>Comparing Envarsus versus Advagraf</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

